Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Fineline Cube Aug 3, 2026
Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Fineline Cube Aug 3, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Fineline Cube Aug 3, 2026
Company Medical Device

Rossum Robot’s Intelligent Surgical Robot for Trauma and Spinal Surgery Clears NMPA Approval

Fineline Cube Feb 23, 2024

Rossum Robot, a Beijing-based developer of orthopedic surgical robots specializing in pelvic fracture procedures, has...

Company Drug

AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval

Fineline Cube Feb 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...

Company Drug

Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis

Fineline Cube Feb 22, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...

Company Drug

FDA Authorizes Biweekly Dosing for J&J’s Tecvayli in Multiple Myeloma Treatment

Fineline Cube Feb 22, 2024

The US Food and Drug Administration (FDA) has granted authorization for a biweekly dosing regimen...

Company

AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael

Fineline Cube Feb 22, 2024

AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has...

Company Deals

Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal

Fineline Cube Feb 22, 2024

China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the...

Company Drug

Immune-Onc Therapeutics’ IO-202 Earns Orphan Drug Designation for CMML from US FDA

Fineline Cube Feb 22, 2024

Immune-Onc Therapeutics, the Hangzhou-based subsidiary of US company Immune-Onc Therapeutics Inc., has announced that it...

Company Drug

Innovent Biologics’ Tyvyt Receives Marketing Approval for Multiple Indications in Macau

Fineline Cube Feb 22, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

Zylox-Tonbridge Receives UAE Approval for Five Medical Devices, Expands Middle East Presence

Fineline Cube Feb 22, 2024

Zylox-Tonbridge (HKG: 2190), a Chinese specialist in medical devices, has announced a series of product...

Company Drug

MSD’s Belzutifan and Sperogenix’s Vamorolone Targeted for Priority Review by China’s CDE

Fineline Cube Feb 22, 2024

The Center for Drug Evaluation (CDE) website has indicated that Merck, Sharp & Dohme’s (MSD;...

Policy / Regulatory

CDE Opens Consultation on 79th Batch of Generic Drug Reference Preparations

Fineline Cube Feb 22, 2024

The Center for Drug Evaluation (CDE) has issued a call for feedback on the 79th...

Company Drug

Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity

Fineline Cube Feb 22, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...

Company Deals

AstraZeneca Secures Shareholder Approval for $1 Billion Acquisition of Gracell Biotechnologies

Fineline Cube Feb 21, 2024

The proposed acquisition of China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) by UK pharmaceuticals giant AstraZeneca...

Policy / Regulatory

FDA Issues Warning Letter to Sichuan Deebio for cGMP Violations in API Manufacturing

Fineline Cube Feb 21, 2024

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Sichuan Deebio...

Company Drug

Bayer Advances BAY3018250 into Phase II Trial Following Successful Phase I Completion

Fineline Cube Feb 21, 2024

Germany’s Bayer (ETR: BAYN) has launched a double-blind, placebo-controlled mid-stage trial for its potential first-in-class...

Company Drug

BMS Seeks FDA Priority Review for Krazati in Advanced Colorectal Cancer

Fineline Cube Feb 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has submitted a priority review application to the U.S....

Company Drug

WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod

Fineline Cube Feb 21, 2024

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...

Company Deals Drug

HitGen’s Vernalis Partners with Hox Therapeutics to Develop Novel Cancer Inhibitors

Fineline Cube Feb 21, 2024

HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D)...

Company Drug

Merck’s Keytruda Under Priority Review for New Indication in Endometrial Carcinoma

Fineline Cube Feb 21, 2024

This week, the U.S. FDA granted priority review status to an indication extension filing from...

Company Deals

Immune-Onc Therapeutics Partners with Roche for Phase Ib/II Study of IO-108 in Liver Cancer

Fineline Cube Feb 21, 2024

Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX:...

Posts pagination

1 … 435 436 437 … 702

Recent updates

  • BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway
  • China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions
  • Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab
  • AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Company Drug

Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.